Corinne Bouvier

Hôpital Européen, Marseille, Marsiglia, Provence-Alpes-Côte d'Azur, France

Are you Corinne Bouvier?

Claim your profile

Publications (107)196.84 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Meningeal solitary fibrous tumors-hemangiopericytomas (SFT-HPC) and meningiomas can be difficult to distinguish on histologic examination. STAT6 immunohistochemistry (IHC) is a reliable diagnostic marker of SFT-HPCs. Recently, GRIA2 has also been reported to be a diagnostic marker of SFT-HPC, although no extensive data are available for meningeal SFT-HPCs yet. The aim of this study was to test their diagnostic performance in a large cohort of SFT-HPCs and meningiomas. IHC analyses for GRIA2 and STAT6 were performed on tissue microarrays containing 76 SFT-HPCs and 181 meningiomas. Results were compared with previous data with ALDH1 and CD34. Two different anti-STAT6 antibodies were tested: SC-20 polyclonal and YE361 monoclonal antibody. Ninety-six percent of meningeal SFT-HPCs but no meningioma displayed nuclear STAT6 positivity. With SC-20 antibody, concomitant cytoplasmic staining for STAT6 was observed in >50% of all cases, including meningiomas. However, using YE361 antibody, cytoplasmic staining was absent, and nuclear signal intensity was stronger leading to better interpretation of STAT6 IHC. GRIA2 was positive in 84% of SFT-HPCs and in 16% of meningiomas. STAT6 had excellent sensitivity (96%) and specificity (100%), ALDH1 and GRIA2 had same sensitivity (84%), but ALDH1 and CD34 had better specificity than GRIA2 (97% and 96% vs. 84%, respectively). For the differential diagnosis of SFT-HPCs versus meningiomas, the best diagnostic approach is to perform STAT6, followed by ALDH1 and CD34 in the case of uncommon STAT6-negative cases. Because of meningioma positivity, GRIA2 seems less useful in this indication.
    The American journal of surgical pathology 10/2015; DOI:10.1097/PAS.0000000000000526 · 5.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HMGA2, CDK4, and JUN genes have been described as frequently coamplified with MDM2 in atypical lipomatous tumor, well-differentiated liposarcoma, and dedifferentiated liposarcoma. We studied the frequency of amplification of these genes in a series of 48 dedifferentiated liposarcomas and 68 atypical lipomatous tumors/well-differentiated liposarcomas. We correlated their amplification status with clinicopathological features and outcomes. Histologically, both CDK4 (P=0.007) and JUN (P=0.005) amplifications were associated with dedifferentiated liposarcoma, whereas amplification of the proximal parts of HMGA2 (5'-untranslated region (UTR) and exons 1-3) was associated with atypical lipomatous tumor/well-differentiated liposarcoma (P=0.01). CDK4 amplification was associated with axial tumors. Amplification of 5'-UTR and exons 1-3 of HMGA2 was associated with primary status and grade 1. Shorter overall survival was correlated with: age >64 years (P=0.03), chemotherapy used in first intent (P<0.001), no surgery (P=0.003), grade 3 (P<0.001), distant metastasis (P<0.001), node involvement (P=0.006), and CDK4 amplification (P=0.07). In multivariate analysis, distant metastasis (HR=8.8) and grade 3 (HR=18.2) were associated with shorter overall survival. A shorter recurrence-free survival was associated with dedifferentiated liposarcoma (P<0.001), grade 3 (P<0.001), node involvement (P<0.001), distant metastasis (P=0.02), recurrent status (P=0.009), axial location (P=0.001), and with molecular features such as CDK4 (P=0.05) and JUN amplification (P=0.07). Amplification of 5'-UTR and exons 1-3 (P=0.08) and 3'-UTR (P=0.01) of HMGA2 were associated with longer recurrence-free survival. Distant metastasis was associated with shorter recurrence-free survival (HR=5.8) in multivariate analysis. Dedifferentiated liposarcoma type was associated with axial location, grade 3 and recurrent status. In conclusion, we showed that the amplification of HMGA2 was associated with the atypical lipomatous tumor/well-differentiated liposarcoma histological type and a good prognosis, whereas CDK4 and JUN amplifications were associated with dedifferentiated liposarcoma histology and a bad prognosis. In addition, we also provided the first description of the molecular evolution of a well-differentiated liposarcoma into four successive dedifferentiated liposarcoma relapses, which was consistent with our general observations.Modern Pathology advance online publication, 4 September 2015; doi:10.1038/modpathol.2015.96.
    Modern Pathology 09/2015; DOI:10.1038/modpathol.2015.96 · 6.19 Impact Factor

  • 06/2015; 48(2). DOI:10.1016/S1286-935X(15)71132-9

  • The American journal of surgical pathology 04/2015; 39(7). DOI:10.1097/PAS.0000000000000461 · 5.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract is missing (Short communication).
    Acta Dermato Venereologica 02/2015; 95(7). DOI:10.2340/00015555-2078 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the usefulness of dynamic gadolinium-enhanced magnetic resonance imaging (MRI) for assessing the viability of the proximal pole of the scaphoid in patients with acute scaphoid fractures. Methods: Eighteen consecutive patients with acute scaphoid fracture who underwent dynamic gadolinium-enhanced MRI 7 days or less before surgery were prospectively included between August 2011 and December 2012. All patients underwent MR imaging with unenhanced images, enhanced images, and dynamic enhanced images. A radiologist first classified the MRI results as necrotic or viable based on T1- and T2-weighted images only, followed by a second blinded interpretation, this time including analysis of pre- and post-gadolinium administration images and a third blinded interpretation based on the time-intensity curve of the dynamic enhanced study. The standard of reference was the histologic assessment of a cylindrical specimen of the proximal pole obtained during surgery in all patients. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for unenhanced, enhanced, and dynamic gadolinium-enhanced MRI studies. Results: The sensitivity, specificity, PPV, and NPV were 67, 67, 50, and 80 % for unenhanced images, 83, 100, 100, and 92 for enhanced images, and 83, 92, 83, and 92 for dynamic contrast-enhanced images. Conclusions: Our data are consistent with previously reported data supporting contrast-enhanced MRI for assessment of viability, and showing that dynamic imaging with time-intensity curve analysis does not provide additional predictive value over standard delayed enhanced imaging for acute scaphoid fracture.
    Skeletal Radiology 08/2014; 43(12). DOI:10.1007/s00256-014-1981-8 · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Langerhans cell histiocytosis of bone is a rare pediatric neoplastic disorder of unclear pathogenesis. We report the case of a 3-year-old girl who presented with Langerhans cell histiocytosis of the ilium in which Kingella kingae was detected. Our findings argue for the search for K. kingae by PCR in children with Langerhans cell histiocytosis of bone.
    The Pediatric Infectious Disease Journal 08/2014; 34(3). DOI:10.1097/INF.0000000000000527 · 2.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The standard therapy regimen of conventional osteosarcoma includes neoadjuvant chemotherapy followed by surgical resection and postoperative chemotherapy. The percentage of necrotic tissue following induction chemotherapy is assessed by using the Huvos grading system, which classifies patients as “poor responders” (PR) and “good responders” (GR). The aim of this study was to identify molecular markers expressed differentially between good and poor responders to neoadjuvant chemotherapy in order to predict the response to chemotherapy in conventional osteosarcomas before beginning treatment. Methods Suppression Substractive Hybridization (SSH) was performed by using cDNA from frozen biopsy specimens. Expression of selected relevant genes identified by SSH was validated by using QRT-PCR. Immunohistochemistry (IHC) on tissue microarray (TMA) sections of 52 biopsies was performed to investigate protein expression in an independent cohort. Results ERK1 and STAT3 mRNA level were significantly different between PR and GR in an independent cohort. Phosphorylated STAT3 and ERK1 expressions by IHC on TMA were correlated with poor response to chemotherapy. Conclusions Our results suggest that ERK1 and STAT3 expression are good predictive markers for chemotherapy response and that inhibitors might be used in combination with common chemotherapeutic drugs in conventional osteosarcomas.
    BMC Cancer 08/2014; 14(1):606. DOI:10.1186/1471-2407-14-606 · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rosai-Dorfman disease of the central nervous system is extremely rare and difficult to diagnose also for pathologists. We describe three unusual cases of meningeal Rosai-Dorfman disease and illustrate the difficulties of preoperative and pathological diagnosis. We retrospectively analyzed three patients who underwent surgery for a suspected meningioma for whom the final diagnosis was Rosai-Dorfman disease of the central nervous system. Pathological initial diagnosis was schwannoma, lymphoplasmacyte-rich meningioma, or inflammatory tumor, but final diagnosis in all cases was Rosai-Dorfman disease. These cases underline the preoperative and pathological difficulties of such diagnosis. Pathologists and physicians should be aware of the occurrence of such rare localization of this disease and should think about this differential diagnosis in lymphocyte-rich meningeal tumors mimicking, clinically and radiologically, a meningioma. Communication of significant previous medical history to pathologists and careful examination of slides with appropriate medical history and the use of S100 antibody in the diagnosis of meningeal tumors mimicking Rosai-Dorfman disease could lower the rate of misdiagnosis.
    Annals of Hematology 12/2013; 93(6). DOI:10.1007/s00277-013-1994-8 · 2.63 Impact Factor

  • 11/2013; 94(11):1181. DOI:10.1016/j.jradio.2013.10.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: L’esame anatomopatologico dei tumori del sistema nervoso centrale è cruciale per la gestione dei pazienti. Esso si basa sulla citologia, sull’esame istopatologico standard dopo l’inclusione in paraffina e su tecniche complementari, come l’immunoistochimica, la biologia molecolare ed eccezionalmente la microscopia elettronica. Un esame estemporaneo è, a volte, realizzato per assicurarsi della rappresentatività del materiale tumorale in caso di biopsie stereotassiche. Un frammento tumorale potrà anche essere congelato per costituire una tumoroteca, se esiste abbastanza materiale. La diagnosi istopatologica consiste nel determinare il tipo di proliferazione tumorale e nel fornire degli elementi prognostici. La classificazione dell’Organizzazione Mondiale della Sanità (OMS) 2007 dei tumori del sistema nervoso centrale distingue i tumori primitivi e quelli secondari. Fra i tumori primitivi, sono i tumori neuroepiteliali, tra cui si distinguono i gliomi, a essere i più frequenti. Ciascuno di essi è definito da criteri istopatologici precisi che permettono di fornire una diagnosi e degli elementi prognostici sotto forma di un grading, a volte controverso, in particolare per i gliomi infiltranti. Numerosi lavori di biologia molecolare hanno evidenziato delle alterazioni genetiche che permettono di descrivere dei modelli di progressione verso la malignità, in particolare per i gliomi infiltranti e i meningiomi. Questi dati si aggiungono alla diagnosi anatomopatologica.
    11/2013; 13(4):1–26. DOI:10.1016/S1634-7072(13)66018-3
  • Source
    P Souteyrand · C Bouvier · J-V Zink · F Chapon · S Marciano · M André · C Chagnaud ·

    Diagnostic and interventional imaging 10/2013; 94(11). DOI:10.1016/j.diii.2013.10.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glial and glioneuronal tumors in children and adult demonstrate distinctive clinical, neuroradiological and molecular features depending on the pathological subtype and within a same subgroup according to the age. In children, gliomas are mainly located in the infratentorial part of the brain. They are most often benign and circumscribed but infiltrative tumors with dismal prognosis are recorded within the pons (DIGP) or the thalamus. Glioblastomas are very rare in children. In contrast, gliomas in adult mainly occur in the cerebral hemispheres and the most frequent subtype is glioblastoma. Glioneuronal tumors mainly occurred in children and young adults. In addition, although pilocytic astrocytomas, pleomorphic xanthoastrocytomas and gangliogliomas are classified into different subgroups according to the WHO 2007 classification, these tumors demonstrate similar neuroradiological findings: they are cystic with contrast enhancement of a mural nodule. Major advances have been made these last five years in the discovery of some master genes that are involved in gliomagenesis and point out differences between children and adults. In adults, infiltrative gliomas can be classified into two major subgroups depending on the existence or not of IDH mutations. IDH-dependent gliomagenesis encompasses diffuse grade II and grade III (they can also show additional molecular alterations such as TP53 mutation or 1p19q codeletion) and secondary glioblastomas. IDH-independent gliomagenesis include triple negative grade II gliomas, gliomatosis cerebri (grade III) and de novo glioblastomas. Pilocytic astrocytomas, pleomorphic xanthoastrocytomas and gangliogliomas share in common BRAF alterations. However, KIAA1549-BRAF fusion characterizes pilocytic astrocytomas whereas V600E BRAF mutation is mainly recorded in pleomorphic xanthoastrocytomas and gangliogliomas.
    Bulletin du cancer 07/2013; 100(7-8). DOI:10.1684/bdc.2013.1789 · 0.60 Impact Factor

  • La Revue de Médecine Interne 06/2013; 34:A175. DOI:10.1016/j.revmed.2013.03.200 · 1.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Solitary Fibrous Tumours (SFT) and haemangiopericytomas (HPC) are rare meningeal tumours that have to be distinguished from meningiomas and more rarely from synovial sarcomas. We recently found that ALDH1A1 was overexpressed in SFT and HPC as compared to soft tissue sarcomas. Using whole-genome DNA microarrays, we defined the gene expression profiles of 16 SFT/HPC (9 HPC and 7 SFT). Expression profiles were compared to publicly available expression profiles of additional SFT or HPC, meningiomas and synovial sarcomas. We also performed an immunohistochemical (IHC) study with anti-ALDH1 and anti-CD34 antibodies on Tissue Micro-Arrays including 38 SFT (25 meningeal and 13 extrameningeal), 55 meningeal haemangiopericytomas (24 grade II, 31 grade III), 163 meningiomas (86 grade I, 62 grade II, 15 grade III) and 98 genetically confirmed synovial sarcomas. Results ALDH1A1 gene was overexpressed in SFT/HPC, as compared to meningiomas and synovial sarcomas. These findings were confirmed at the protein level. 84% of the SFT and 85.4% of the HPC were positive with anti-ALDH1 antibody, while only 7.1% of synovial sarcomas and 1.2% of meningiomas showed consistent expression. Positivity was usually more diffuse in SFT/HPC compared to other tumours with more than 50% of tumour cells immunostained in 32% of SFT and 50.8% of HPC. ALDH1 was a sensitive and specific marker for the diagnosis of SFT (SE = 84%, SP = 98.8%) and HPC (SE = 84.5%, SP = 98.7%) of the meninges. In association with CD34, ALDH1 expression had a specificity and positive predictive value of 100%. Conclusion We show that ALDH1, a stem cell marker, is an accurate diagnostic marker for SFT and HPC, which improves the diagnostic value of CD34. ALDH1 could also be a new therapeutic target for these tumours which are not sensitive to conventional chemotherapy.
    05/2013; 1(1). DOI:10.1186/2051-5960-1-10

  • 04/2013; 94(4):482–485. DOI:10.1016/j.jradio.2012.09.015
  • [Show abstract] [Hide abstract]
    ABSTRACT: I tumori del sistema nervoso periferico (SNP) comprendono dei tumori benigni, essenzialmente rappresentati dagli schwannomi e dai neurofibromi, e dei tumori maligni, raggruppati sotto il termine di tumori maligni della guaina dei nervi periferici (malignant peripheral nerve sheath tumours [MPNST]). Questi tumori sono sporadici o si sviluppano nell’ambito di una facomatosi. La neurofibromatosi di tipo 1 (NF1) si caratterizza per la presenza di neurofibromi e di eventuali tumori maligni della guaina dei nervi periferici. Gli schwannomi multipli sono un criterio diagnostico della neurofibromatosi di tipo 2 (NF2). Gli schwannomi o neurinomi sono dei tumori ben delimitati che realizzano una massa eccentrica sul tragitto di un nervo. In istologia, la proliferazione è costituita da cellule di Schwann organizzate in fasci compatti (zone A di Antoni) o in zone più lasse ed edematose (zone B di Antoni). I nuclei delle cellule possono allinearsi e realizzare delle palizzate che delimitano degli spazi che corrispondono ai noduli di Vérocay, numerosi nelle zone A di Antoni. Le cellule tumorali esprimono la proteina S100 in immunoistochimica. I neurofibromi sono dei tumori mal delimitati, spesso cutanei. Quando si sviluppano sul tragitto di un nervo, essi determinano un aumento di volume fusiforme. La proliferazione tumorale è costituita da cellule di Schwann, da cellule perineurali e da fibroblasti organizzati su un fondo mixoide. Il trattamento degli schwannomi e dei neurofibromi consiste in un’exeresi chirurgica. I tumori maligni delle guaine dei nervi periferici si sviluppano in più del 50% dei casi in un contesto di NF1. Macroscopicamente si tratta di tumori a crescita rapida che determinano frequentemente dei rimaneggiamenti necroticoemorragici e un marcato potere di invasione locoregionale e, in seguito, generale. L’istologia mostra una proliferazione di cellule fusiformi con un’alternanza di zone compatte e di zone più lasse. Le cellule presentano delle atipie citonucleari ed esprimono la proteina S100 in modo più eterogeneo e più debole che nei tumori benigni. Si tratta, in genere, di tumori ad alto grado di malignità e la loro prognosi è riservata. Più recentemente, sono stati descritti dei MPNST a basso grado di malignità. Nel 15% dei casi, esistono degli aspetti morfologici inconsueti, con un aspetto epitelioide oppure una differenziazione divergente: tumore di Triton e MPNST ghiandolare. Il trattamento rimane essenzialmente chirurgico. In alcuni casi una chemioterapia sarà discussa in una riunione di concertazione interdisciplinare.
    04/2013; 13(2):1–11. DOI:10.1016/S1634-7072(13)64487-6
  • P Souteyrand · C Bouvier · J-V Zink · F Chapon · S Marciano · M André · C Chagnaud ·

    Diagnostic and interventional imaging 03/2013; 94(4). DOI:10.1016/j.diii.2013.01.008
  • G. de Pinieux · C. Bouvier · A. Brouchet · P. Rosset ·
    [Show abstract] [Hide abstract]
    ABSTRACT: La conducta médica inicial ante el hallazgo de un tumor óseo primario es fundamental, pues permite definir la mejor estrategia diagnóstica y terapéutica. Desde luego, la asistencia médica ha de ser multidisciplinaria. Esto conduce a la elección del método de biopsia diagnóstica y a la vía de acceso más adecuada. En el menor tiempo posible, la biopsia se enviará en «estado fresco» al patólogo, quien ha de repartir el material (fijación, congelación, etc.) según la cantidad, la calidad o los presuntos diagnósticos. Se conocen unas 50 formas de tumores óseos primarios, distribuidas en 12 clases principales. Algunas de estas formas, sobre todo los condrosarcomas, cuentan con una clasificación histopronóstica específica.
    02/2013; 46(1):1–15. DOI:10.1016/S1286-935X(13)64175-1
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: GNAS (guanine nucleotide-binding protein/α-subunit) mutations that induce the activation of G-protein α-subunit participate in the pathogenesis of fibrous dysplasia. The aim of this study was to evaluate the sensitivity and specificity of GNAS mutations in fibrous dysplasia and other fibro-osseous lesions, to assess the value of investigating this mutation in the diagnosis of fibro-osseous lesions. We studied 91 cases of fibrous dysplasia. The quality and/or quantity of genomic DNA were suitable for molecular analysis for 51 cases of fibrous dysplasia. GNAS mutations were investigated by three techniques: high-resolution melting (exon 8), allele-specific PCR (exons 8 and 9) and/or direct DNA sequencing (exons 8 and 9). Fibrous dysplasia samples were classified blind to the GNAS mutation status into six histological subtypes as conventional, fibro-involutive, osteosclerosing, cementifying, osteocartilaginous and with prominent aneurysmal cystic changes. We also studied 14 cases of low-grade osteosarcoma, 21 cases of ossifying fibroma, 3 cases of osteofibrous dysplasia, 1 case of osseous dysplasia of the jawbone and 1 post-traumatic lesion of the ribs. Twenty-three cases of fibrous dysplasia (45%) showed mutations of codon 201 (exon 8, p.R201H or p.R201C). No mutation was found on codon 227 (exon 9). GNAS mutations in conventional fibrous dysplasia were detected in the same proportion (47%) as in the other histological subtypes (47%, P=0.96), regardless of sex (P=0.44), age (P=0.90) and location (P=1). GNAS mutations were not detected in any other fibro-osseous lesions. The GNAS mutation was thus specific to fibrous dysplasia in the context of fibro-osseous lesions. The particular mosaicism of mutant and non-mutant cells within the lesion or the existence of other mutations not already described could explain the lack of GNAS mutation in cases of fibrous dysplasia. Investigating this mutation may constitute a valuable complementary diagnostic tool, despite its low sensitivity, particularly in unconventional morphologically different subtypes of fibrous dysplasia.
    Modern Pathology 02/2013; 26(7). DOI:10.1038/modpathol.2012.223 · 6.19 Impact Factor

Publication Stats

892 Citations
196.84 Total Impact Points


  • 2008-2015
    • Hôpital Européen, Marseille
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2008-2014
    • Aix-Marseille Université
      • Faculté de Médecine
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2010
    • Institut de Recherche sur les Phénomènes Hors Equilibre
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2009-2010
    • Assistance Publique Hôpitaux de Marseille
      • Service de chirurgie orthopédique et pédiatrique
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2003
    • University Hospital Estaing of Clermont-Ferrand
      Clermont, Auvergne, France